Ultrasound contrast agent developer Sonus Pharmaceuticals has taken control of its EchoGen agent from partner Abbott Laboratories of Abbott Park, IL, with Sonus assuming responsibility for U.S. marketing related to EchoGen.
Abbott, which returned the rights at no cost to Sonus, will have no further economic responsibilities to Sonus, of Bothell, WA. As previously announced, Abbott will continue to manufacture EchoGen until mid-2002, however.
Sonus plans to implement a dedicated clinical sales force for EchoGen that will be managed and trained by Sonus through a contract sales organization, according to president and CEO Michael Martino. EchoGen is approved for marketing in the European Union, and is under review by the Food and Drug Administration.
By AuntMinnie.com staff writers
April 5, 2000
